- Report
- October 2024
- 195 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- October 2024
- 185 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
From €3868EUR$4,250USD£3,316GBP
- Report
- June 2023
- 159 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Report
- June 2023
- 80 Pages
Global
From €3595EUR$3,950USD£3,082GBP
- Report
- January 2024
- 95 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- July 2024
- 280 Pages
Global
From €2416EUR$2,655USD£2,071GBP
- Book
- February 2018
- 448 Pages
- Book
- April 2022
- 656 Pages
Global
The Vinca Alkaloids market is a subset of the Oncology Drugs market, focusing on drugs derived from the Vinca plant. These drugs are used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. Vinca Alkaloids are used to treat cancer by inhibiting the growth of cancer cells and preventing them from spreading. They are also used to reduce the side effects of chemotherapy and radiation therapy.
Vinca Alkaloids are available in both generic and branded forms, and are typically administered intravenously or orally. The market is highly competitive, with a number of companies offering different formulations of the drugs.
Some of the major companies in the Vinca Alkaloids market include Bristol-Myers Squibb, Pfizer, Merck, Novartis, and Eli Lilly. These companies are involved in the research, development, and marketing of Vinca Alkaloids. Show Less Read more
